Viewing nowNanubia Tablets 25 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
HuTechs Pharmaceutical Co., Ltd.

MFDS item code 202101255 · Approved 2021.02.10 · Insurance code 649105250
Improvement of blood glucose control in type 2 diabetes mellitus
This medication is used in conjunction with dietary control and exercise therapy to help manage blood sugar levels in patients with type 2 diabetes. It may be administered alone at the beginning of treatment. If blood sugar control is difficult with monotherapy, it may be used together with metformin. If sufficient blood sugar control is not achieved with other diabetes treatments such as sulfonylureas, metformin, thiazolidinedione, or insulin, this medication can be added as an adjunct therapy. It effectively improves blood sugar control tailored to various treatment situations.
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication can cause rare but serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur after taking this medication, stop taking it immediately and consult a healthcare professional. This medication can cause pancreatitis, which is inflammation of the pancreas, so notify a healthcare professional immediately if symptoms such as abdominal pain, vomiting, or nausea occur. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, nor should individuals with hypersensitivity to this medication or its ingredients. Patients with reduced kidney function should have their dosages adjusted, and regular kidney function tests are important. Hypoglycemia can occur while taking this medication, especially when used with insulin or sulfonylureas, so blood glucose levels should be monitored closely and dosages adjusted as necessary. This medication can cause serious side effects such as severe joint pain or blistering dermatitis, so consult a doctor immediately if any of these symptoms occur. Pregnant or breastfeeding women are advised not to take this medication, and safety and efficacy have not been established in children or adolescents under 18 years of age. Older patients may have reduced kidney function, so it is necessary to periodically check kidney function before and during treatment with this medication. In case of an overdose, general symptomatic treatment is performed, and renal dialysis may be required to remove the medication if necessary. This medication generally has less interaction with other hypoglycemic agents, but caution is needed when used with certain medications, so it is important to inform healthcare professionals of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.
Pink, round, biconvex film-coated tablet
28 tablets / box [(14 tablets / PTPX2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
HuTechs Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.